# Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate

> **NCT00955760** · PHASE1 · COMPLETED · sponsor: **Merz Pharmaceuticals GmbH**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Neramexane

## Key facts

- **NCT ID:** NCT00955760
- **Lead sponsor:** Merz Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** — (—)
- **Last updated:** 2011-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00955760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00955760, "Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00955760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*